NEW YORK (GenomeWeb) – Genomics England announced today that it will use GenomOncology's GO Knowledge Management System (KMS) to help analyze cancer samples from the 100,000 Genomes Project.
The GO KMS enables the aggregation and analysis of biomarker-based data within a framework that includes annotations such as genes, pathways, drugs, alterations, transcripts, and disease ontology, and uses data from a number of sources including US Food and Drug Administration, American Society of Clinical Oncology, and National Comprehensive Cancer Network guidelines.
Genomics England said it will combine the system with its own curated database to augment its clinical reporting for the 100,000 Genomes Project's cancer program, and that it will work with GenomOncology to extend the GO KMS to include guidelines from the UK’s National Institute for Health and Care Excellence and UK-specific clinical trials.
"GenomOncology brings to the table a widely used knowledge base, as the people behind My Cancer Genome," Augusto Rendon, director of bioinformatics at Genomics England, said in a statement. "Through exhaustive curation by the My Cancer Genome team, GenomOncology has made great progress in solving the difficult problem of representing cancer variants consistently in order to support genomic workflows."
Genomics England has inked deals with other bioinformatics firms to assist with the 100,000 Genomes Project including agreements with Icon in February and WuXi Nextcode late last year.